| MDL | MFCD27987937 |
|---|---|
| Molecular Weight | 272.31 |
| Molecular Formula | C12H16N8 |
| SMILES | CN1C(N2N=CC=N2)=NC3=C1N=C(CCCC)N=C3N |
ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease [1] [2] .
|
A2a adenosine receptor |
ST 1535 (0, 5, 10 mg/kg; p.o.) antagonizes catalepsy induced by i.c.v. administration with the A2A adenosine agonist
CGS 21680
(HY-13201)
[1]
.
ST 1535 (10, 20, 40 mg/kg; i.p.) increases the number of contralateral turns induced by
l-DOPA
(HY-N0304) in rats
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 5-6 weeks CD1 male mice [1] |
| Dosage: | 0, 5, 10 mg/kg |
| Administration: | P.o. |
| Result: | Antagonized catalepsy induced by i.c.v. administration with the A2A adenosine agonist CGS 21680. |
| Animal Model: | Male Sprague Dawley rats [2] |
| Dosage: | 10, 20, 40 mg/kg |
| Administration: | I.p. |
| Result: | Significantly increased the number of contralateral turns induced by l-DOPA (3 mg/kg i.p.) at 20 and 40 mg/kg. |
Room temperature in continental US; may vary elsewhere.
Please store the product under the recommended conditions in the Certificate of Analysis.